Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | MLNR | O43193 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314829 | 0.95 | CCR3 (0.41) | ALDH1A1CCR2MLNRRAB9ALMNA | |
| SCHEMBL3313172 | 0.85 | PARP10 (0.46) | ALDH1A1SMN1; SMN2CCR2NPC1RAB9A | |
| SCHEMBL3316461 | 0.82 | L3MBTL1 (0.41) | ALDH1A1SMN1; SMN2L3MBTL1PKMLIPE | |
| SCHEMBL3315505 | 0.79 | CCR2 (0.46) | CCR2TRPV1PDE10A | |
| SCHEMBL3313736 | 0.77 | LTA4H (0.44) | ALDH1A1SMN1; SMN2L3MBTL1PKMLIPE | |
| SCHEMBL3317034 | 0.74 | CCR2 (0.45) | CCR2TRPV1PDE10A | |
| SCHEMBL3313789 | 0.69 | FAAH (0.46) | ALDH1A1SMN1; SMN2RAB9AHPGDLMNA | |
| SCHEMBL3313029 | 0.69 | CCR2 (0.46) | CCR2TRPV1 | |
| SCHEMBL3022615 | 0.67 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2MLNRLMNATP53 | |
| SCHEMBL3316036 | 0.66 | CCR2 (0.42) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | ALDH1A1 1255/4885SMN1; SMN2 784/4885CCR2 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.